Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic.
Chaves ALF, Castro AF, Marta GN, Junior GC, Ferris RL, Giglio RE, Golusinski W, Gorphe P, Hosal S, Leemans CR, Magné N, Mehanna H, Mesía R, Netto E, Psyrri A, Sacco AG, Shah J, Simon C, Vermorken JB, Kowalski LP. Chaves ALF, et al. Among authors: mesia r. Oral Oncol. 2020 Aug;107:104734. doi: 10.1016/j.oraloncology.2020.104734. Epub 2020 Apr 24. Oral Oncol. 2020. PMID: 32353793 Free PMC article. No abstract available.
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Bernier J, et al. Among authors: mesia r. Ann Oncol. 2008 Jan;19(1):142-9. doi: 10.1093/annonc/mdm400. Epub 2007 Sep 4. Ann Oncol. 2008. PMID: 17785763 Free article.
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Vermorken JB, et al. Among authors: mesia r. N Engl J Med. 2007 Oct 25;357(17):1695-704. doi: 10.1056/NEJMoa071028. N Engl J Med. 2007. PMID: 17960012 Free article. Clinical Trial.
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Vermorken JB, et al. Among authors: mesia r. N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656. N Engl J Med. 2008. PMID: 18784101 Free article. Clinical Trial.
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB. Mesía R, et al. Ann Oncol. 2010 Oct;21(10):1967-1973. doi: 10.1093/annonc/mdq077. Epub 2010 Mar 24. Ann Oncol. 2010. PMID: 20335368 Free PMC article. Clinical Trial.
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
van Herpen CM, Mauer ME, Mesia R, Degardin M, Jelic S, Coens C, Betka J, Bernier J, Remenar E, Stewart JS, Preiss JH, van den Weyngaert D, Bottomley A, Vermorken JB; EORTC Head and Neck Group. van Herpen CM, et al. Among authors: mesia r. Br J Cancer. 2010 Oct 12;103(8):1173-81. doi: 10.1038/sj.bjc.6605860. Epub 2010 Sep 14. Br J Cancer. 2010. PMID: 20842129 Free PMC article. Clinical Trial.
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Licitra L, Mesia R, Rivera F, Remenár É, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB. Licitra L, et al. Among authors: mesia r. Ann Oncol. 2011 May;22(5):1078-1087. doi: 10.1093/annonc/mdq588. Epub 2010 Nov 3. Ann Oncol. 2011. PMID: 21048039 Free PMC article. Clinical Trial.
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, Kerber A, Bethe U, Picard M, Brummendorf TH. Vermorken JB, et al. Among authors: mesia r. Br J Cancer. 2011 May 24;104(11):1691-6. doi: 10.1038/bjc.2011.152. Epub 2011 May 3. Br J Cancer. 2011. PMID: 21540865 Free PMC article. Clinical Trial.
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM. Vermorken JB, et al. Among authors: mesia r. Ann Oncol. 2014 Mar;25(3):682-688. doi: 10.1093/annonc/mdu003. Ann Oncol. 2014. PMID: 24567516 Free PMC article. Clinical Trial.
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
Vermorken JB, Psyrri A, Mesía R, Peyrade F, Beier F, de Blas B, Celik I, Licitra L. Vermorken JB, et al. Among authors: mesia r. Ann Oncol. 2014 Apr;25(4):801-807. doi: 10.1093/annonc/mdt574. Epub 2014 Feb 26. Ann Oncol. 2014. PMID: 24577117 Free PMC article.
145 results